Phyllis A. Gimotty

32.6k citations

240 papers · 20.1k indexed · 7 hit papers · h-index 60

Oncology top 0.05%
Molecular Biology top 0.5%
Immunology top 0.2%
Cancer Research top 0.2%
Epidemiology top 1%

Co-authors: George Coukos Lin Zhang Dionyssios Katsaros Stephen C. Rubin José R. Conejo-García M Massobrio Antonis Makrigiannakis Katia Schlienger
Topics: Cutaneous Melanoma Detection and Management (50 papers)Immunotherapy and Immune Responses (31 papers)Melanoma and MAPK Pathways (19 papers)
Cited by: Oncology Immunology Cancer Research
Journals: Nature New England Journal of Medicine Cell
Partner nations: United States Italy Canada

In The Last Decade

Phyllis A. Gimotty

229 papers receiving 19.7k citations

Hit Papers

5 papers align trajectories

What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

Final Version of 2009 AJCC Melanoma Staging and Classification

2009 3.3k citations Charles M. Balch, Jeffrey E. Gershenwald et al. Journal of Clinical Oncology profile →
Intratumoral T Cells, Recurrence, and Survival in Epithelial Ovarian Cancer

2003 2.6k citations Lin Zhang, Dionyssios Katsaros et al. profile →
Tumour hypoxia promotes tolerance and angiogenesis via CCL28 and Treg cells

2011 1.1k citations Andrea Barchetti, Phyllis A. Gimotty et al. profile →
A Temporarily Distinct Subpopulation of Slow-Cycling Melanoma Cells Is Required for Continuous Tumor Growth

2010 872 citations Alexander Roesch, Devraj Basu et al. profile →
microRNAs exhibit high frequency genomic alterations in human cancer

2006 829 citations Lin Zhang, Jia Huang et al. profile →
The microRNAs miR-373 and miR-520c promote tumour invasion and metastasis

2008 800 citations Andres J. Klein–Szanto, Phyllis A. Gimotty et al. profile →
Overcoming Intrinsic Multidrug Resistance in Melanoma by Blocking the Mitochondrial Respiratory Chain of Slow-Cycling JARID1Bhigh Cells

2013 487 citations Alexander Roesch, David W. Speicher et al. profile →

Peers

Countries citing papers authored by Phyllis A. Gimotty

Since Specialization

Citations

This map shows the geographic impact of Phyllis A. Gimotty's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Phyllis A. Gimotty with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Phyllis A. Gimotty more than expected).

Fields of papers citing papers by Phyllis A. Gimotty

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Phyllis A. Gimotty. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Phyllis A. Gimotty. The network helps show where Phyllis A. Gimotty may publish in the future.

Co-authorship network of co-authors of Phyllis A. Gimotty

This figure shows the co-authorship network connecting the top 25 collaborators of Phyllis A. Gimotty. A scholar is included among the top collaborators of Phyllis A. Gimotty based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Phyllis A. Gimotty. Phyllis A. Gimotty is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work	Indexed citations
1	SARS-CoV-2–specific T cells in unexposed adults display broad trafficking potential and cross-react with commensal antigens 2022 ·Science Immunology ·(unknown),Sumbul Afroz,(unknown),(unknown),(unknown),(unknown),Ceylan Tanes,Kyle Bittinger,Elliot S. Friedman,Phyllis A. Gimotty,Gary D. Wu,Laura F. Su	29
2	Targeting UGCG Overcomes Resistance to Lysosomal Autophagy Inhibition 2022 ·Cancer Discovery ·Vaibhav Jain,Sandra L. Harper,(unknown),Dylan Fingerman,(unknown),Monika Bhardwaj,Mary Ann S. Crissey,Aaron R. Goldman,Gordon Ruthel,Qin Liu,Aleksandra Živković,(unknown),Meenhard Herlyn,Phyllis A. Gimotty,David W. Speicher,Ravi K. Amaravadi	18
3	Autophagy Inhibition to Augment mTOR Inhibition: a Phase I/II Trial of Everolimus and Hydroxychloroquine in Patients with Previously Treated Renal Cell Carcinoma 2019 ·Clinical Cancer Research ·Naomi B. Haas,Leonard J. Appleman,Mark N. Stein,Maryann Redlinger,(unknown),Xiaowei Xu,Angelique Onorati,(unknown),Tae Hyong Kim,Chao Jie Zhen,Sabah Kadri,Jeremy P. Segal,Phyllis A. Gimotty,Lisa E. Davis,Ravi K. Amaravadi	112
4	Oncogenic RAS Regulates Long Noncoding RNA Orilnc1 in Human Cancer 2017 ·Cancer Research ·Dongmei Zhang,Gao Zhang,Zhongyi Hu,Lawrence W. Wu,Yi Feng,(unknown),Youyou Zhang,Lu Yang,Tian Tian,Weiting Xu,Zhi Wei,Yiling Lu,Keith T. Flaherty,Xiaomin Zhong,Gordon B. Mills,Phyllis A. Gimotty,Xiaowei Xu,Meenhard Herlyn,Lin Zhang	29
5	JARID1B Enables Transit between Distinct States of the Stem-like Cell Population in Oral Cancers 2016 ·Cancer Research ·Nicole D. Facompre,(unknown),Xavier Solé,Sheheryar Kabraji,(unknown),Varun Sahu,Kelly A. Whelan,Koji Tanaka,Gregory S. Weinstein,Kathleen T. Montone,Alexander Roesch,Phyllis A. Gimotty,Meenhard Herlyn,Anil K. Rustgi,Hiroshi Nakagawa,Sridhar Ramaswamy,Devraj Basu	37
6	DNMT3A Mutational Status Affects the Results of Dose-Escalated Induction Therapy in Acute Myelogenous Leukemia 2015 ·Clinical Cancer Research ·Alison R. Sehgal,Phyllis A. Gimotty,Jianhua Zhao,Jingmei Hsu,Robert Daber,Jennifer D. Morrissette,Selina M. Luger,Alison W. Loren,Martin Carroll	39
7	CTLA-4 Blockade Synergizes Therapeutically with PARP Inhibition in BRCA1-Deficient Ovarian Cancer 2015 ·Cancer Immunology Research ·Tomoe Higuchi,Dallas B. Flies,Nicole A. Marjon,Gina Mantia-Smaldone,Lukas Ronner,Phyllis A. Gimotty,Sarah F. Adams	235
8	EGFR Inhibition Promotes an Aggressive Invasion Pattern Mediated by Mesenchymal-like Tumor Cells within Squamous Cell Carcinomas 2013 ·Molecular Cancer Therapeutics ·Devraj Basu,Arnaud F. Bewley,Steven M. Sperry,Kathleen T. Montone,Phyllis A. Gimotty,Kati Räsänen,Nicole D. Facompre,Gregory S. Weinstein,Hiroshi Nakagawa,J. Alan Diehl,Anil K. Rustgi,Meenhard Herlyn	18
9	Prognostic Significance of Mitotic Rate in Localized Primary Cutaneous Melanoma: An Analysis of Patients in the Multi-Institutional American Joint Committee on Cancer Melanoma Staging Database 2011 ·Journal of Clinical Oncology ·John F. Thompson,Seng-Jaw Soong,Charles M. Balch,Jeffrey E. Gershenwald,Shouluan Ding,Daniel G. Coit,Keith T. Flaherty,Phyllis A. Gimotty,T. M. Johnson,Marcella M. Johnson,Stanley P. L. Leong,Merrick I. Ross,David R. Byrd,Natale Cascinelli,Alistair J. Cochran,Alexander M.M. Eggermont,Kelly M. McMasters,Martín C. Mihm,Donald L. Morton,Vernon K. Sondak	250
10	A NOTCH3-Mediated Squamous Cell Differentiation Program Limits Expansion of EMT-Competent Cells That Express the ZEB Transcription Factors 2011 ·Cancer Research ·Shinya Ohashi,Mitsuteru Natsuizaka,Seiji Naganuma,Shingo Kagawa,(unknown),Hiroshi Itoh,Ross A. Kalman,Momo Nakagawa,Douglas S. Darling,Devraj Basu,Phyllis A. Gimotty,Andres J. Klein–Szanto,J. Alan Diehl,Meenhard Herlyn,Hiroshi Nakagawa	89
11	Periostin, a Cell Adhesion Molecule, Facilitates Invasion in the Tumor Microenvironment and Annotates a Novel Tumor-Invasive Signature in Esophageal Cancer 2010 ·Cancer Research ·Carmen Z. Michaylira,Gabrielle S. Wong,Charles G. Miller,(unknown),Hiroshi Nakagawa,Rachel Hammond,Andres J. Klein–Szanto,Ju‐Seog Lee,Sang Bae Kim,Meenhard Herlyn,J. Alan Diehl,Phyllis A. Gimotty,Anil K. Rustgi	97
12	CXCR3 expression is associated with poor survival in breast cancer and promotes metastasis in a murine model 2009 ·Molecular Cancer Therapeutics ·Xinrong Ma,Kelly J. Norsworthy,Namita Kundu,William H. Rodgers,Phyllis A. Gimotty,Olga Goloubeva,Michael Lipsky,Yanchun Li,Dawn Holt,Amy M. Fulton	124
13	Final Version of 2009 AJCC Melanoma Staging and Classificationbreakdown → 2009 ·Journal of Clinical Oncology ·Charles M. Balch,Jeffrey E. Gershenwald,Seng-Jaw Soong,John F. Thompson,Michael B. Atkins,David R. Byrd,Antônio C. Buzaid,Alistair J. Cochran,Daniel G. Coit,Shouluan Ding,Alexander M.M. Eggermont,Keith T. Flaherty,Phyllis A. Gimotty,John M. Kirkwood,Kelly M. McMasters,Martín C. Mihm,Donald L. Morton,Merrick I. Ross,Arthur J. Sober,Vernon K. Sondak	3342
14	In vivo modeling and detection of the ovarian cancer vascular marker TEM1 2008 ·Clinical Cancer Research ·(unknown),Jennifer L. Swails,Kosei Hasegawa,Ann O’Brien-Jenkins,(unknown),Wafik S. El‐Deiry,Nathalie Scholler,Chaitanya Divgi,Phyllis A. Gimotty,George Coukos	1
15	Identification of a Gene Signature for Rapid Screening of Oral Squamous Cell Carcinoma 2006 ·Clinical Cancer Research ·Amy Ziober,Kirtesh R. Patel,Faizan Alawi,Phyllis A. Gimotty,Randall S. Weber,Michaël Feldman,Ara A. Chalian,Gregory S. Weinstein,Jennifer L. Hunt,Barry L. Ziober	88
16	Integrative Genomic Analysis of Protein Kinase C (PKC) Family Identifies PKCι as a Biomarker and Potential Oncogene in Ovarian Carcinoma 2006 ·Cancer Research ·Lin Zhang,Jia Huang,Nuo Yang,Shun Liang,Andrea Barchetti,Antonis Giannakakis,Mark G. Cadungog,Ann O’Brien-Jenkins,M Massobrio,Katherine F. Roby,Dionyssios Katsaros,Phyllis A. Gimotty,Ralf Bützow,Barbara L. Weber,George Coukos	109
17	Variability in nomenclature used for nevi with architectural disorder and cytologic atypia (microscopically dysplastic nevi) by dermatologists and dermatopathologists 2004 ·Journal of Cutaneous Pathology ·Michael B. Shapiro,Mary‐Margaret Chren,Ross M. Levy,David E. Elder,Philip E. LeBoit,Martín C. Mihm,David J. Margolis,Phyllis A. Gimotty,Michael E. Ming	32
18	Delivering Preventive Health Services for Breast Cancer Control: A Longitudinal View of a Randomized Controlled Trial 2002 ·Health Services Research ·Phyllis A. Gimotty,Robert C. Burack,Julie George	6
19	Imputation procedures for categorical data: their effects on the goodness-of-fit chi-square statistic 1990 ·Communications in Statistics - Simulation and Computation ·Phyllis A. Gimotty,Morton B. Brown	3
20	Detroit's avoidable mortality project: breast cancer control for inner-city women. 1990 ·PubMed ·(unknown),Phyllis A. Gimotty,William Stengle,(unknown),L H Warbasse,Anita Moncrease	40

About Phyllis A. Gimotty

Phyllis A. Gimotty is a scholar working on Oncology, Immunology and Hematology, having authored 240 papers that have together received 20.1k indexed citations. Recurring topics across this work include Cutaneous Melanoma Detection and Management (50 papers), Immunotherapy and Immune Responses (31 papers) and Melanoma and MAPK Pathways (19 papers). The work is most often cited by research in Oncology (10.5k citations), Immunology (5.6k citations) and Cancer Research (3.9k citations). Phyllis A. Gimotty has collaborated with scholars based in United States, Italy and Canada. Frequent co-authors include George Coukos, Lin Zhang, Dionyssios Katsaros, Stephen C. Rubin, José R. Conejo-García, M Massobrio, Antonis Makrigiannakis, Katia Schlienger, Heidi J. Gray and Michael Liebman. Their work appears in journals such as Nature, New England Journal of Medicine and Cell.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact